The Honest Dose #4

A few weeks ago I made a post about collagen on reddit. Nothing provocative, just an honest question about why a compound with solid human RCT evidence still gets dismissed as "just protein" by people who are otherwise careful about what they put in their bodies.

The thread did well. But what stayed with me wasn't the engagement numbers. It was watching people in the comments move past the evidence conversation toward stuff that had almost no human data at all. Someone mentioned a peptide stack they were running. Another person brought up a fasting protocol they'd read about on a forum. The collagen discussion, with its actual controlled trials and replication across independent research groups, became almost beside the point.

I've been sitting with that observation ever since. PeptideClear exists to give people accurate information about what the evidence actually shows. But I'm not naive enough to think that information alone changes minds that are already pointed somewhere. If someone comes to the site looking for confirmation that BPC-157 is safe and effective, the Research Quality Score (RQS) score of 23 isn't going to stop them. They'll read the animal data, note that the mechanism is plausible, and decide the risk is acceptable to them. Which is their right.

What I keep coming back to is whether the platform's job is to inform decisions or to change them. I think it's the former. The honest version of what PeptideClear does is give people a clearer picture of the evidence landscape, not tell them what to do with it. That framing keeps me from over claiming what a catalog can actually accomplish, and it keeps me honest about the fact that some of our visitors will find exactly what they came looking for, even if the data doesn't fully support it.

Not sure I've resolved that tension. But it felt worth naming.

Let's get into it.

Thymosin Alpha-1 is a 28-amino acid peptide derived from thymosin fraction 5, a protein originally isolated from calf thymus tissue in the 1970s by Allan Goldstein at George Washington University. The synthetic version, trademarked as Zadaxin by SciClone Pharmaceuticals, has been approved in 35+ countries for use in hepatitis B, hepatitis C, and as an immune adjuvant in cancer and immunocompromised patients.

In the United States, it has never received FDA approval. It is not on the FDA's approved drug list, not widely prescribed, and essentially invisible in mainstream American medicine. That gap between its international regulatory footprint and its US status is one of the stranger stories in the catalog.

Thymosin Alpha-1 acts as an immune modulator, it doesn't simply "boost" immunity in the blunt way supplement marketing tends to imply, but rather helps calibrate the immune response. Its primary mechanisms include stimulating T-cell maturation and differentiation, enhancing dendritic cell function, upregulating cytokine production (particularly Th1 cytokines like IL-2 and interferon-gamma), and supporting NK cell activity.

The distinction between immune stimulation and immune modulation matters here. Stimulation is the premise behind most "immune support" supplements, the idea that more immune activity is inherently better. Modulation is a more precise concept: the immune system needs to be calibrated, not just revved up. Thymosin Alpha-1's documented effects suggest it works on the calibration side, which is part of why its clinical applications have been in patients with specific immune dysfunction rather than healthy adults seeking general immune support.

Thymosin Alpha-1 has the highest RQS in the catalog at 94/100, tied with GLP-1 and one point above Tirzepatide. That score reflects something real: this compound has decades of Phase III RCT data across multiple indications, replicated by independent research groups across Asia, Europe, and the US.

The hepatitis B evidence is the strongest. Multiple Phase III trials, published in Hepatology and Journal of Hepatology (impact factors of 17 and 25 respectively), demonstrated consistent virological responses. Meta-analyses covering thousands of patients show meaningful, replicable effects. The evidence base here is not preliminary or contested, it's the kind of data that gets drugs approved.

The COVID-19 chapter added another dimension that would have seemed speculative a decade ago. Multiple Chinese RCTs published between 2020 and 2022 tested Thymosin Alpha-1 in severe COVID-19 patients, finding reductions in mortality and improvements in immune recovery markers. These were prospective trials with pre-specified endpoints, not retrospective data pulls. The results were consistent enough to prompt broader clinical interest in its use for sepsis and critical illness, areas where immune dysregulation, not just infection, drives outcomes.

What it hasn't shown is meaningful benefit in healthy adults seeking general immune enhancement. The clinical populations where it works are defined by specific immune dysfunction: chronic viral infections, chemotherapy-induced immunosuppression, critical illness. That's not a failure of the compound, it's a reflection of what targeted immunomodulation is actually for.

Zadaxin received approval in dozens of countries primarily because hepatitis B is a major public health burden in Asia, where SciClone built its commercial footprint. The US hepatitis B population was smaller and already being served by interferon-based therapies when the pivotal trials ran. SciClone never pursued a US NDA.

The result is a compound with an RQS that matches GLP-1, a drug that has reshaped medicine and generated tens of billions in revenue, sitting in an American regulatory gray zone, available only through compounding pharmacies for off-label use, largely unknown outside of infectious disease circles.

It's one of the starker examples of what the FDA approval process does and doesn't capture. Approval reflects commercial decisions and US-specific trial history as much as it reflects scientific merit.

If you're immunocompromised, managing a chronic viral infection, or undergoing chemotherapy, Thymosin Alpha-1 has a stronger evidence base than almost anything else in the catalog. If you're a healthy adult trying to "support your immune system," the evidence doesn't support using it for that purpose, and you probably don't need what it's actually doing.

The more interesting question this compound raises is what "evidence-based" medicine means when regulatory approval is as much a function of market economics as it is of science.

RQS: 94/100 — Strong Evidence

Read the full Thymosin Alpha-1 profile

The claim: Certain supplements, echinacea, high-dose vitamin C, zinc, elderberry, strengthen your immune system and reduce how often you get sick. The immune health supplement market is now approaching $85 billion globally. The marketing premise behind most of it is that more immune activity means better immune function.

The reality: The evidence for most immune supplements in healthy adults is weak, inconsistent, or misrepresented. And the "boost your immunity" framework is biologically imprecise in a way that actually matters.

Vitamin C is the canonical case. Linus Pauling's high-dose vitamin C work generated enormous popular interest in the 1970s. Subsequent RCTs have consistently failed to replicate meaningful cold prevention in healthy adults who aren't deficient or under extreme physical stress (marathon runners, military personnel in subarctic conditions being the exception). Cochrane reviews, the gold standard for synthesizing RCT evidence, conclude that vitamin C supplementation does not reduce cold incidence in healthy adults. Duration may be slightly shortened. But the "take vitamin C to avoid getting sick" claim isn't what the best evidence shows.

Echinacea is messier. Some preparations from specific species show modest effects on cold duration in some trials. Others show nothing. The evidence is inconsistent enough that drawing a confident conclusion is difficult, which is itself useful information when the marketing is confident.

Zinc lozenges have decent evidence for reducing cold duration when started early, but the mechanism is local (coating the upper respiratory mucosa) rather than systemic immune enhancement. It also causes nausea and can permanently impair smell at high doses. The risk-benefit calculus is narrower than the "zinc boosts immunity" framing suggests.

The honest version of the claim: Most immune supplements don't prevent illness in healthy adults. Some have modest effects on duration or severity under specific conditions. "Boosting" immunity isn't a coherent biological goal, the immune system isn't a battery that benefits from being charged up. Thymosin Alpha-1, ironically, has better evidence than any of the above, and its mechanism (modulation, not stimulation) is more consistent with how immunology actually works.

The $85 billion market is largely selling a feeling of proactive health management that the evidence doesn't support in most cases.

Building out the Thymosin Alpha-1 profile surfaced something worth sharing: the COVID-19 RCT data from China is more substantive than most Western audiences realize.

Between 2020 and 2022, multiple prospective Chinese trials tested Thymosin Alpha-1 in severe COVID-19 patients. These weren't small observational studies, some were pre-registered RCTs with mortality as a primary endpoint. The findings were consistent: reductions in 28-day mortality, improvements in lymphocyte recovery, better outcomes in patients with severe immune dysregulation.

These trials appear in journals most US clinicians don't routinely read, conducted in a system most Western medical audiences don't closely track. The evidence exists and is methodologically sound. It's just not in the conversations.

This is a different version of the Russian literature problem from Issue #3. It's not that the science is weak, it's that research published primarily in Chinese clinical journals, in the context of an emergency healthcare response, doesn't travel the same channels as a NEJM trial. The compound's RQS reflects the full evidence base. Whether that evidence reaches decision-makers in the US is a different question.

GLP-1 drugs may reduce metastatic cancer progression — presented at ASCO 2026. A Cleveland Clinic real-world analysis of 12,000+ patients found that people taking GLP-1 medications were 38% to 50% less likely to progress to stage IV cancer in four tumor types: lung, breast, colorectal, and liver. The study compared GLP-1 users to DPP-4 inhibitor users with matched cancer types and comorbidities. The findings are not yet peer-reviewed, and randomized trials are needed before this changes clinical practice. But the signal at that sample size is hard to dismiss, and it adds to a growing body of evidence suggesting GLP-1s may have direct anti-tumor effects beyond weight loss. Reuters covered it this week. Worth watching for the peer-reviewed publication.

The immune supplement market is approaching $85 billion, most of it is not evidence-based. Global immune health supplement sales are projected to reach $85 billion in 2026, up from $68 billion in 2024. The fastest-growing segments are herbal and botanical ingredients, personalized nutrition, and functional foods marketed around immunity. The gap between market size and evidentiary support for most products in this category is substantial. Thymosin Alpha-1, a compound with 35+ country approvals and Phase III RCT data, is essentially absent from this market. The compounds dominating it have a fraction of its evidence base. That asymmetry is worth sitting with.

Thymosin Alpha-1's COVID-19 RCT data deserves more attention than it's getting. While building out the Thymosin Alpha-1 profile, I kept running into a body of prospective Chinese RCTs from 2020 to 2022 that tested it in severe COVID-19 pre-registered trials with mortality endpoints, not retrospective data pulls. The findings were consistent and the methodology was sound. This data contributed to its 94/100 RQS. It hasn't generated much Western clinical discussion, which is partly a publishing ecosystem issue and partly a function of when and where the trials ran. If you're interested in immunomodulation beyond the supplement aisle, these trials are worth reading.

A compound that takes a different path to FDA approval than anything else discussed in this issue.

PT-141, marketed as Vyleesi, is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works via melanocortin receptors in the brain, specifically MC4R, which are involved in sexual arousal pathways. Unlike most sexual health compounds, it acts centrally rather than peripherally, it doesn't affect blood flow the way PDE5 inhibitors like sildenafil (Viagra) do. It changes the brain's signaling environment around desire.

The RECONNECT Phase III trials enrolled 1,247 women and demonstrated statistically significant improvements in desire and reductions in distress. FDA approved it in 2019. The evidence for male sexual dysfunction is smaller, Phase II level, but the mechanism translates.

RQS: 69/100 — Moderate Evidence

It's a genuinely interesting compound because its approval path is straightforward by pharmaceutical standards, yet it's almost completely absent from mainstream health conversations. Most people who've heard of peptides for sexual health know about it by its research chemical name. Fewer know it has an FDA-approved formulation with a well-characterized clinical trial record.

Read the full PT-141 profile

Hopefully that was helpful/interesting, see you next week.

-Emeka

You're receiving this because you signed up at peptideclear.com. No sponsors. No affiliate links. Just the research, translated.